Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 13/20 | 0.72 |
| ▸ | NPC1 | O15118 | 8/20 | 0.72 |
| ▸ | RAB9A | P51151 | 8/20 | 0.72 |
| ▸ | MAPT | P10636 | 6/20 | 0.72 |
| ▸ | GLA | P06280 | 2/20 | 0.72 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 5/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | CCR1 | P32246 | 2/20 | 0.52 |
| ▸ | CCR5 | P51681 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3069800 | 0.84 | KDM4E (1.00) | KDM4ENPC1RAB9AMAPTGLA | |
| SCHEMBL1771878 | 0.83 | KDM4E (0.50) | KDM4ENPC1RAB9AMAPTGLA | |
| SCHEMBL28857293 | 0.82 | KDM4E (0.95) | KDM4ENPC1RAB9AMAPTGLA | |
| SCHEMBL7865703 | 0.78 | HDAC1 (0.52) | KDM4ENPC1RAB9AMAPTGLA | |
| SCHEMBL146382 | 0.77 | KDM4E (0.75) | KDM4ENPC1RAB9AMAPTGLA | |
| SCHEMBL10960575 | 0.75 | KDM4E (0.72) | KDM4ENPC1RAB9AMAPTGLA | |
| SCHEMBL20382465 | 0.75 | KDM4E (0.72) | KDM4ENPC1RAB9AMAPTGLA | |
| SCHEMBL21258329 | 0.75 | KDM4E (0.72) | KDM4ENPC1RAB9AMAPTGLA | |
| SCHEMBL3847476 | 0.75 | KDM4E (0.72) | KDM4ENPC1RAB9AMAPTGLA | |
| SCHEMBL3827117 | 0.75 | KDM4E (0.72) | KDM4ENPC1RAB9AMAPTGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113801170-A | Bromine atom modified blue light absorption enhanced iridium (III) complex and preparation method thereof | 东莞理工学院 | 2021-12-17 | — | — | CN | claimed |
| US-6605707-B1 | Etherification; reacting erythromycin derivative with propargyl derivative and alkali alkoxide; reacting with acid and sodium nitrite | ABBOTT LABORATORIES | 2003-08-12 | — | — | US | claimed |
| EP-1265909-A2 | PROCESS FOR THE PREPARATION OF 6-O-PROPARGYL ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 2002-12-18 | — | — | EP | claimed |
| WO-2001077134-A2 | PROCESS FOR THE PREPARATION OF 6-O-PROPARGYL ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 2001-10-18 | — | — | WO | claimed |
| CN-118894889-A | Platinum (II) complex material with self-photosensitive catalysis and preparation method and application thereof | 东莞理工学院 | 2024-11-05 | — | — | CN | disclosed |
| US-20230303573-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | Grünenthal GmbH (DE) | 2023-09-28 | — | — | US | disclosed |
| CN-112074507-B | Compounds as Antibiotics | 山东亨利医药科技有限责任公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-113801170-A | Bromine atom modified blue light absorption enhanced iridium (III) complex and preparation method thereof | 东莞理工学院 | 2021-12-17 | — | — | CN | disclosed |
| CN-108602834-B | Bruton's tyrosine kinase inhibitor | 北京盛诺基医药科技股份有限公司 | 2021-01-08 | — | — | CN | disclosed |
| US-20200392096-A1 | COMPOUND ACTING AS ANTIBIOTICS | KBP BIOSCIENCES CO., LTD. (CN) | 2020-12-17 | — | — | US | disclosed |
| US-20200392096-A1 | COMPOUND ACTING AS ANTIBIOTICS | KBP BIOSCIENCES CO., LTD. (CN) | 2020-12-17 | — | — | US | disclosed |
| EP-3750881-A1 | COMPOUND ACTING AS ANTIBIOTICS | KBP Biosciences Co., Ltd. (CN) | 2020-12-16 | — | — | EP | disclosed |
| WO-2000055168-A1 | 6-O-SUBSTITUTED MACROLIDES HAVING ANTIBACTERIAL ACTIVITY | ABBOTT LABORATORIES (US) | 2000-09-21 | — | — | WO | disclosed |
| US-6054435-A | 6-O-substituted macrolides having antibacterial activity | ABBOTT LABORATORIES (US) | 2000-04-25 | — | — | US | disclosed |
| WO-1999043285-A2 | SULPHONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1999-09-02 | — | — | WO | disclosed |
| EP-0937708-A2 | sulphonamide derivatives | ELI LILLY AND COMPANY (US) | 1999-08-25 | — | — | EP | disclosed |
| US-5260294-A | Treatment of diseases caused by oxidative metabolism of arachidonic acid; antiinflammatory, antiallergins, antiarthriric | HOFFMAN-LA ROCHE INC. (US) | 1993-11-09 | — | — | US | disclosed |
| US-5132310-A | Benzochroman compounds, lipoxygenase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 1992-07-21 | — | — | US | disclosed |
| US-5015661-A | Lipoxygenase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 1991-05-14 | — | — | US | disclosed |
| EP-0354508-A2 | Benzopyranol derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1990-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303573-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | KDM4E 2919/4885NPC1 2990/4885RAB9A 3308/4885 |
| US-20200392096-A1 | COMPOUND ACTING AS ANTIBIOTICS | PEPD, NRDC, DPP4 | KDM4E 1834/4885NPC1 277/4885RAB9A 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.